{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:03:45Z","timestamp":1790525025489,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/s41408-018-0066-7","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T02:14:30Z","timestamp":1522808070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma"],"prefix":"10.1038","volume":"8","author":[{"given":"Shengjian","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0772-8710","authenticated-orcid":false,"given":"Makhdum","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle","family":"Nomie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"66_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","volume":"142","author":"P Jares","year":"2008","unstructured":"Jares, P. & Campo, E. Advances in the understanding of mantle cell lymphoma. Br. J. Haematol.\n                           142, 149\u2013165 (2008).","journal-title":"Br. J. Haematol."},{"key":"66_CR2","first-page":"1291","volume":"85","author":"SA Pileri","year":"2000","unstructured":"Pileri, S. A. et al. The pathologist\u2019s view point. Part I--indolent Lymphomas Haematol.\n                           85, 1291\u20131307 (2000). 11\/30\/2017; 01\/15\/2018.","journal-title":"Part I--indolent Lymphomas Haematol."},{"key":"66_CR3","unstructured":"Chiron D., et al. Microenvironment-dependent proliferation and mitochondrial priming loss in mantle cell lymphoma is overcome by anti-CD20. Blood. 6, 720490 (2016)."},{"key":"66_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/bjh.12537","volume":"163","author":"B Coiffier","year":"2013","unstructured":"Coiffier, B. et al. A multicentre, phase II trial of ofatumumab monotherapy in relapsed\/progressive diffuse large B\u2010cell lymphoma. Br. J. Haematol.\n                           163, 334\u2013342 (2013).","journal-title":"Br. J. Haematol."},{"key":"66_CR5","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","volume":"27","author":"F Morschhauser","year":"2009","unstructured":"Morschhauser, F. et al. Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin\u2019s lymphoma: phase I\/II results. J. Clin. Oncol.\n                           27, 3346\u20133353 (2009).","journal-title":"J. Clin. Oncol."},{"key":"66_CR6","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","volume":"21","author":"F Morschhauser","year":"2010","unstructured":"Morschhauser, F. et al. Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma. Ann. Oncol.\n                           21, 1870\u20131876 (2010).","journal-title":"Ann. Oncol."},{"key":"66_CR7","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","volume":"31","author":"FA Morschhauser","year":"2013","unstructured":"Morschhauser, F. A. et al. Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J. Clin. Oncol.\n                           31, 2912\u20132919 (2013).","journal-title":"J. Clin. Oncol."},{"key":"66_CR8","doi-asserted-by":"crossref","unstructured":"Wirth R., et al. CD20-specific engineered toxin body demonstrates direct cell kill of multiple B-cell non-Hodgkin\u2019s lymphoma types. Blood. 122, 5152 (2013).","DOI":"10.1182\/blood.V122.21.5152.5152"},{"key":"66_CR9","doi-asserted-by":"crossref","unstructured":"Huang S., et al. Preclinical examination of the effects of MT-3724, an engineered toxin body targeting CD20, in mantle cell lymphoma. AACR; 2017.","DOI":"10.1158\/1538-7445.AM2017-3651"},{"key":"66_CR10","doi-asserted-by":"crossref","unstructured":"Fanale M. A., et al. Abstract CT049: Phase I\/Ib study of the novel CD20-targeted immunotoxin MT-3724 in relapsed\/refractory non-Hodgkin\u2019s B-cell lymphoma. AACR; 2016.","DOI":"10.1158\/1538-7445.AM2016-CT049"},{"key":"66_CR11","doi-asserted-by":"crossref","unstructured":"Willert E. K., et al. Engineered toxin bodies: A next-generation immunotoxin scaffold with novel immuno-oncology functionality. AACR; 2015.","DOI":"10.1158\/1538-7445.AM2015-2477"},{"key":"66_CR12","doi-asserted-by":"crossref","unstructured":"Rajagopalan S., et al. CD20-specific Engineered Toxin Body demonstrates direct cell kill of multiple B-cell Non-Hodgkin\u2019s lymphoma types. AACR; 2014.","DOI":"10.1182\/blood.V122.21.5152.5152"},{"key":"66_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New Engl. J. Med.\n                           369, 507\u2013516 (2013).","journal-title":"New Engl. J. Med."},{"key":"66_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/bjh.13427","volume":"170","author":"S Zhang","year":"2015","unstructured":"Zhang, S., Smith, S., Zhang, S. & Lynn, W. Y. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br. J. Haematol.\n                           170, 445 (2015).","journal-title":"Br. J. Haematol."},{"key":"66_CR15","doi-asserted-by":"publisher","first-page":"101042831769222","DOI":"10.1177\/1010428317692226","volume":"39","author":"H Allahyari","year":"2017","unstructured":"Allahyari, H., Heidari, S., Ghamgosha, M., Saffarian, P. & Amani, J. Immunotoxin: A new tool for cancer therapy. Tumor Biol.\n                           39, 1010428317692226 (2017).","journal-title":"Tumor Biol."},{"key":"66_CR16","doi-asserted-by":"publisher","first-page":"G811","DOI":"10.1152\/ajpgi.2000.278.5.G811","volume":"278","author":"NL Jones","year":"2000","unstructured":"Jones, N. L. et al. Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am. J. Physiol. Gastrointest. Liver Physiol.\n                           278, G811\u2013G819 (2000).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"66_CR17","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1128\/IAI.71.3.1497-1504.2003","volume":"71","author":"WE Smith","year":"2003","unstructured":"Smith, W. E. et al. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect. Immun.\n                           71, 1497\u20131504 (2003).","journal-title":"Infect. Immun."},{"key":"66_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0882-4010(03)00100-1","volume":"35","author":"RD Erwert","year":"2003","unstructured":"Erwert, R. D. et al. Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb. Pathog.\n                           35, 87\u201393 (2003).","journal-title":"Microb. Pathog."},{"key":"66_CR19","doi-asserted-by":"crossref","unstructured":"Zhang L., et al. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin. Cancer Res. 23, 4212\u20134223 (2017).","DOI":"10.1158\/1078-0432.CCR-16-2703"},{"key":"66_CR20","doi-asserted-by":"crossref","unstructured":"Robinson G. L., et al. MT-3724, an engineered toxin body targeting CD20 for non-Hodgkin\u2019s lymphoma. AACR; 2016.","DOI":"10.1158\/1538-7445.AM2016-1483"},{"key":"66_CR21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron, D. et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov.\n                           4, 1022\u20131035 (2014).","journal-title":"Cancer Discov."},{"key":"66_CR22","doi-asserted-by":"crossref","unstructured":"Huang S., et al. Pre-clinical evaluation of the PI3K-p110\u03b2\/\u03b4 inhibitor KA2237 in mantle cell lymphoma. Am. Soc. Hematol. (2016).","DOI":"10.1182\/blood.V128.22.1837.1837"},{"key":"66_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med.\n                           19, 202\u2013208 (2013).","journal-title":"Nat. Med."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0066-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0066-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0066-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:34:20Z","timestamp":1671536060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0066-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["66"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0066-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"30 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"33"}}